Gold prices edge up amid Fed rate cut hopes; US-Russia talks awaited
Investing.com - Ionis Pharma (NASDAQ: IONS) reported fourth quarter EPS of $-0.66, $0.45 better than the analyst estimate of $-1.11. Revenue for the quarter came in at $227M versus the consensus estimate of $135.58M.
Guidance
Ionis Pharma sees FY 2025 revenue of $600.00M versus the analyst consensus of $677.10M.
Ionis Pharma’s stock price closed at $31.95. It is down -6.06% in the last 3 months and down -27.96% in the last 12 months.
Ionis Pharma saw 6 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Ionis Pharma’s stock price’s past reactions to earnings here.
According to InvestingPro, Ionis Pharma’s Financial Health score is "fair performance".
Check out Ionis Pharma’s recent earnings performance, and Ionis Pharma’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar